The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.
Khanh Tu Do
No relevant relationships to disclose
Deborah Wilsker
No relevant relationships to disclose
Priya Balasubramanian
No relevant relationships to disclose
Jennifer Zlott
No relevant relationships to disclose
Woondong Jeong
No relevant relationships to disclose
Scott M Lawrence
No relevant relationships to disclose
Robert J. Kinders
No relevant relationships to disclose
Jerry Collins
No relevant relationships to disclose
Alice P. Chen
No relevant relationships to disclose
James H. Doroshow
No relevant relationships to disclose
Shivaani Kummar
No relevant relationships to disclose